160 related articles for article (PubMed ID: 28606047)
21. Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.
Pratt LM; Beckett RP; Davies SJ; Launchbury SB; Miller A; Spavold ZM; Todd RS; Whittaker M
Bioorg Med Chem Lett; 2001 Oct; 11(19):2585-8. PubMed ID: 11551755
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationship analysis of the peptide deformylase inhibitor 5-bromo-1H-indole-3-acetohydroxamic acid.
Petit S; Duroc Y; Larue V; Giglione C; Léon C; Soulama C; Denis A; Dardel F; Meinnel T; Artaud I
ChemMedChem; 2009 Feb; 4(2):261-75. PubMed ID: 19053131
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
Hu L; Cai X; Dong S; Zhen Y; Hu J; Wang S; Jiang J; Huang J; Han Y; Qian Y; Yuan Y; Hu W
J Med Chem; 2020 Jul; 63(13):6959-6978. PubMed ID: 32551649
[TBL] [Abstract][Full Text] [Related]
24. New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
Lv F; Chen C; Tang Y; Wei J; Zhu T; Hu W
Bioorg Med Chem Lett; 2016 Aug; 26(15):3714-8. PubMed ID: 27293070
[TBL] [Abstract][Full Text] [Related]
25. 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents.
Gupta MK; Mishra P; Prathipati P; Saxena AK
Bioorg Med Chem; 2002 Dec; 10(12):3713-6. PubMed ID: 12413827
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of peptide deformylase inhibitors.
Chen D; Yuan Z
Expert Opin Investig Drugs; 2005 Sep; 14(9):1107-16. PubMed ID: 16144495
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of 4'-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methyl)biphenyl-2-carbonitrile analogs as bacterial peptide deformylase inhibitors.
Khan FA; Patil RH; Shinde DB; Sangshetti JN
Chem Biol Drug Des; 2016 Dec; 88(6):938-944. PubMed ID: 27401234
[TBL] [Abstract][Full Text] [Related]
28. Docking studies of nickel-peptide deformylase (PDF) inhibitors: exploring the new binding pockets.
Wang Q; Zhang D; Wang J; Cai Z; Xu W
Biophys Chem; 2006 Jun; 122(1):43-9. PubMed ID: 16545516
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
[TBL] [Abstract][Full Text] [Related]
30. Alpha-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents.
Jain R; Sundram A; Lopez S; Neckermann G; Wu C; Hackbarth C; Chen D; Wang W; Ryder NS; Weidmann B; Patel D; Trias J; White R; Yuan Z
Bioorg Med Chem Lett; 2003 Dec; 13(23):4223-8. PubMed ID: 14623006
[TBL] [Abstract][Full Text] [Related]
31. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
[TBL] [Abstract][Full Text] [Related]
32. Chiral Pool Synthesis, Biological Evaluation and Molecular Docking Studies of C-Furanosidic LpxC Inhibitors.
Dreger A; Kharwb O; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
ChemMedChem; 2019 Apr; 14(8):871-886. PubMed ID: 30801965
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin.
Van Aller GS; Nandigama R; Petit CM; DeWolf WE; Quinn CJ; Aubart KM; Zalacain M; Christensen SB; Copeland RA; Lai Z
Biochemistry; 2005 Jan; 44(1):253-60. PubMed ID: 15628866
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and PDF inhibitory activities of novel benzothiazolylidenehydroxamic acid derivatives.
Takayama W; Shirasaki Y; Sakai Y; Nakajima E; Fujita S; Sakamoto-Mizutani K; Inoue J
Bioorg Med Chem Lett; 2003 Oct; 13(19):3273-6. PubMed ID: 12951107
[TBL] [Abstract][Full Text] [Related]
35. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.
Hackbarth CJ; Chen DZ; Lewis JG; Clark K; Mangold JB; Cramer JA; Margolis PS; Wang W; Koehn J; Wu C; Lopez S; Withers G; Gu H; Dunn E; Kulathila R; Pan SH; Porter WL; Jacobs J; Trias J; Patel DV; Weidmann B; White RJ; Yuan Z
Antimicrob Agents Chemother; 2002 Sep; 46(9):2752-64. PubMed ID: 12183225
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the methylene spacer and the P1' side chain.
Davies SJ; Ayscough AP; Beckett RP; Bragg RA; Clements JM; Doel S; Grew C; Launchbury SB; Perkins GM; Pratt LM; Smith HK; Spavold ZM; Thomas SW; Todd RS; Whittaker M
Bioorg Med Chem Lett; 2003 Aug; 13(16):2709-13. PubMed ID: 12873499
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
[TBL] [Abstract][Full Text] [Related]
38. Bacterial Peptide deformylase inhibition of cyano substituted biaryl analogs: Synthesis, in vitro biological evaluation, molecular docking study and in silico ADME prediction.
Khan FA; Patil RH; Shinde DB; Sangshetti JN
Bioorg Med Chem; 2016 Aug; 24(16):3456-63. PubMed ID: 27269198
[TBL] [Abstract][Full Text] [Related]
39. Structure-Based Drug Design of Small Molecule Peptide Deformylase Inhibitors to Treat Cancer.
Gao J; Wang T; Qiu S; Zhu Y; Liang L; Zheng Y
Molecules; 2016 Mar; 21(4):396. PubMed ID: 27023495
[TBL] [Abstract][Full Text] [Related]
40. Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.
Hu X; Nguyen KT; Jiang VC; Lofland D; Moser HE; Pei D
J Med Chem; 2004 Sep; 47(20):4941-9. PubMed ID: 15369398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
